Retatrutide vs Tirzepatide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Retatrutide
Retatrutide (LY3437943) is a first-in-class triple agonist peptide targeting GIP, GLP-1, and glucagon receptors simultaneously. Developed by Eli Lilly, it is currently in Phase 3 clinical trials and has demonstrated the highest weight loss of any obesity medication to date — up to 28.7% body weight reduction at 48 weeks. The triple-receptor mechanism represents the next evolution beyond dual agonists like tirzepatide.
Full details →Tirzepatide
Tirzepatide is the first dual GIP/GLP-1 receptor agonist — a 39-amino acid synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors. FDA-approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). In clinical trials, tirzepatide demonstrated greater weight loss than semaglutide, with up to 22.5% body weight reduction at the highest dose.
Full details →Side-by-Side Comparison
| Aspect | Retatrutide | Tirzepatide |
|---|---|---|
| Mechanism | Retatrutide is a synthetic peptide that activates three incretin/metabolic hormone receptors: (1) GLP-1 receptor — appetite suppression, insulin secretion, delayed gastric emptying, (2) GIP receptor — enhanced insulin sensitivity, improved fat metabolism, (3) Glucagon receptor — increased energy expenditure, hepatic fat mobilization, thermogenesis. The glucagon receptor component is the key differentiator, adding an energy-expenditure mechanism absent from GLP-1 and dual GIP/GLP-1 agonists. The molecule uses a C20 fatty diacid for albumin binding, enabling once-weekly dosing. | Tirzepatide is based on the GIP peptide sequence with modifications enabling dual agonism at both GIP and GLP-1 receptors. GIP receptor activation enhances the effects of GLP-1 signaling: (1) potentiated insulin secretion beyond GLP-1 alone, (2) improved beta-cell function, (3) enhanced adipose tissue signaling that may improve fat metabolism, (4) potential protection against GLP-1-induced nausea via GIP receptor activity. The peptide has a C20 fatty diacid moiety enabling albumin binding and once-weekly dosing (half-life ~5 days). The dual mechanism explains the superior weight loss and glycemic outcomes compared to selective GLP-1 agonists. |
| Typical Dosage | Phase 2 trial doses: 0.5 mg, 4 mg, 8 mg, and 12 mg weekly. The 12 mg dose produced maximum weight loss (28.7%). Phase 3 trials are evaluating doses up to 12 mg. Dose escalation schedule similar to other GLP-1s (start low, increase every 4 weeks). Final approved dosing not yet established — Phase 3 trials ongoing. | For weight management (Zepbound): start at 2.5 mg weekly for 4 weeks. Escalate to 5 mg for 4 weeks, then 7.5 mg for 4 weeks, then 10 mg. May increase to 12.5 mg, then maximum 15 mg weekly. For type 2 diabetes (Mounjaro): same escalation schedule, maintenance at 5 mg, 10 mg, or 15 mg based on glycemic response. |
| Administration | Subcutaneous injection, once weekly. Phase 3 trials use pre-filled single-dose pens. Not yet commercially available — estimated FDA approval ~2027-2028. | Subcutaneous injection in the abdomen, thigh, or upper arm. Rotate injection sites. Pre-filled single-dose pen — no reconstitution needed. Store refrigerated before first use; may be stored at room temperature (up to 86°F) for up to 21 days. Administer on the same day each week; may change the day if the last dose was given 3+ days prior. |
| Side Effects | Phase 2 data: nausea (up to 25%), diarrhea (up to 22%), vomiting (up to 15%), constipation, decreased appetite. GI side effects were dose-dependent and generally mild-to-moderate. Lower rates of nausea compared to semaglutide, potentially due to GIP component. Increased heart rate observed at higher doses. | Very common (>10%): nausea (up to 33%), diarrhea (up to 25%), decreased appetite, vomiting, constipation, dyspepsia, abdominal pain. Generally milder GI side effects than semaglutide, potentially due to GIP receptor co-activation. Common (1-10%): injection site reactions, fatigue, hypersensitivity reactions, GERD, hair loss, eructation. |
| Best For |
What They Have in Common
Retatrutide, Tirzepatide are both commonly used for:
Detailed Analysis
Commonalities
Both Retatrutide and Tirzepatide are commonly used for Fat Loss.
Which Should You Choose?
Both peptides have similar evidence levels for their shared goals. Your choice may depend on specific use case, availability, or personal response.
Ready to Learn More?
Looking for trusted sources?